Structured treatment interruptions to control HIV-1 and limit drug exposure

Trends in Immunology

Volumn 22, Issue 2, 2001, Pages 92-96

  Montaner, Luis J ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2;

DRUG EXPOSURE; DRUG POTENCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION COMPLICATION; INFECTION CONTROL; NONHUMAN; REVIEW; TREATMENT PLANNING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ACUTE DISEASE; ANTI-HIV AGENTS; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; HIV-1; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RISK FACTORS;

EID: 0034925505     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(00)01809-3     Document Type: Review

References (43)

1. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
2. Resistance, fitness, adherence, and potency: Mapping the paths to virologic failure
3. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
4. What is missing in immunology to understand immunity?
5. Infection-immunity in experimental salmonellosis
6. + T helper cells in the cytotoxic T lymphocyte response to HIV-1
7. + T cell response to HIV-1
8. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors
9. Cellular immune responses to HIV-1 in progressive and non-progressive infections
10. Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly-exposed persistently seronegative donors
11. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
12. Immune control of HIV-1 after early treatment of acute infection
13. + T cell responses associated with control of viremia
14. + T lymphocytes
15. + lymphocytes
16. + repertoire during antiviral therapy
17. + T cell homeostasis and function in advanced HIV disease
18. Lymph node architecture preceding and following 6 months of potent antiviral therapy: Follicular hyperplasia persists in parallel with p24 antigen restoration after involution and CD4 cell depletion in an AIDS patient
19. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
20. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy
21. Antiretroviral resistance during successful therapy of HIV type 1 infection
22. Control of HIV despite the discontinuation of antiretroviral therapy
23. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy
24. Containment of simian immunodeficiency virus infection: Cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment
25. Maximum suppression of HIV replication leads to the restoration of HIV- specific responses in early HIV disease
26. + T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease
27. + T cells produce antiviral cytokines but are impaired in cytolytic function
28. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption
29. Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppression
30. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
31. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors
32. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy
33. The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy
34. + T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy
35. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression
36. Immunization with live attenuated simian immunodeficiency virus induces strong type 1 T helper responses and β-chemokine production
37. Is interruption of HIV therapy always harmful?
38. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment
39. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype
40. Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report
41. Control of SIV rebound through structured treatment interruptions during early infection
42. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails To control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection
43. Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection